株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

白内障:パイプライン製品の分析

Cataract - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 200936
出版日 ページ情報 英文 43 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.77円で換算しております。
Back to Top
白内障:パイプライン製品の分析 Cataract - Pipeline Review, H1 2017
出版日: 2017年05月16日 ページ情報: 英文 43 Pages
概要

白内障は、通常は透明な水晶体が曇り、視野を失うという疾患です。主な症状としては、視野が曇ったり、ぼやけたりかすんだりすることや、夜間にものが見えづらくなること、色覚が失われたり黄色くなったりすること、単眼複視、眼鏡の度数を頻繁に変える必要が出てくることなどが挙げられます。主な疾病素質には年齢や糖尿病、過剰飲酒、高血圧、肥満、喫煙などがあります。

当レポートでは、世界各国での白内障治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などを調査しています。

イントロダクション

  • 調査範囲

白内障 - 概要

白内障 - 治療薬の開発

  • パイプラインの概要
  • 企業別のパイプライン動向
  • 大学・研究機関別のパイプライン動向
  • 企業で開発中の製品
  • 大学・研究機関で開発中の製品

白内障 - 治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

白内障の治療薬開発に従事している企業

  • Acucela Inc
  • EyeGate Pharmaceuticals Inc
  • Genisphere LLC
  • Johnson & Johnson
  • Omeros Corp
  • Plex Pharmaceuticals Inc

薬剤プロファイル

白内障 - 休止中のプロジェクト

白内障 - 開発が中止された製品

白内障 - 製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9287IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cataract - Pipeline Review, H1 2017, provides an overview of the Cataract (Ophthalmology) pipeline landscape.

Cataract is a clouding of the normally clear lens of eye that affects vision. Symptoms include clouded, blurred or dim vision, increasing difficulty with vision at night, fading or yellowing of colors, double vision in a single eye and frequent prescription changes in eye wear. Risk factors include age, diabetes, drinking excessive amounts of alcohol, high blood pressure, obesity and smoking.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cataract - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Cataract (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cataract (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Cataract and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 1, 6 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Cataract (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cataract (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Cataract (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cataract (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cataract (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cataract (Ophthalmology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cataract (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cataract (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Cataract - Overview
    • Cataract - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Cataract - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Cataract - Companies Involved in Therapeutics Development
    • Acucela Inc
    • EyeGate Pharmaceuticals Inc
    • Genisphere LLC
    • Johnson & Johnson
    • Omeros Corp
    • Plex Pharmaceuticals Inc
  • Cataract - Drug Profiles
    • CAT-1001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CAT-811 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dexamethasone acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GL-249 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lanosterol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Non-Surgical Cataracts and Multiple Sclerosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize GPR161 for Central Nervous System Disorders, Oncology and Ophthalmology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit NFkB for Ophthalmology, Oncology and Immunology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Ophthalmology and CNS Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Target Beta-L Crystallin for Cataract and Presbyopia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VP-1001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Cataract - Dormant Projects
  • Cataract - Discontinued Products
  • Cataract - Product Development Milestones
    • Featured News & Press Releases
      • Sep 07, 2016: Plex Pharmaceuticals awarded $299,173 NIH Phase I SBIR grant funding to find non-surgical treatments for Cataracts
      • May 13, 2012: Calpain Therapeutics Wins Commercialisation Australia Grant To Progress Anti-Cataract Programme
      • Sep 04, 2011: New Drug Eyes Way To Beat Cataracts
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Cataract, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Cataract - Pipeline by Acucela Inc, H1 2017
  • Cataract - Pipeline by EyeGate Pharmaceuticals Inc, H1 2017
  • Cataract - Pipeline by Genisphere LLC, H1 2017
  • Cataract - Pipeline by Johnson & Johnson, H1 2017
  • Cataract - Pipeline by Omeros Corp, H1 2017
  • Cataract - Pipeline by Plex Pharmaceuticals Inc, H1 2017
  • Cataract - Dormant Projects, H1 2017
  • Cataract - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Cataract, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top